A menu-driven facility for sample-size calculation in novel multiarm, multistage randomized controlled trials with a time-to-event outcome

20Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We present menu- and command-driven Stata programs for the calculation of sample size, number of events, and trial duration for a novel type of clinical trial design with a time-to-event outcome and two or more experimental arms. The approach is based on terminating accrual of patients to inferior experimental treatment arms at an early stage in the trial, allowing through to the next stage only treatments that show a predefined degree of advantage against the control treatment. The first stage of testing uses an intermediate outcome measure for the definitive (primary) outcome rather than with the primary outcome itself. The experimental arms are compared pairwise with the control arm according to the intermediate outcome measure. Arms that survive the comparison enter the next stage of patient accrual, culminating in comparisons against control on the primary outcome measure. The features supported include unequal patient allocation, target hazard ratios that may differ from 1 under the null hypothesis, and the ability to stop patient recruitment at a specified time after trial initiation. The computations of sample size and power are based on the asymptotic mean and variance of the log hazard-ratio under the null and alternative hypotheses. The overall operating characteristics are computed from the intermediate and final stage significance levels and power, and the correlation between the log hazard-ratios on the intermediate and primary outcome measures at the different stages. We illustrate the approach with the design of a United Kingdom Medical Research Council six-arm trial in prostate cancer in which the intermediate outcome is failure-free survival and the primary outcome is overall survival. © 2009 StataCorp LP.

References Powered by Scopus

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

2826Citations
N/AReaders
Get full text

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial

532Citations
N/AReaders
Get full text

Criteria for the validation of surrogate endpoints in randomized experiments

366Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

1636Citations
N/AReaders
Get full text

Abiraterone for prostate cancer not previously treated with hormone therapy

1377Citations
N/AReaders
Get full text

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

952Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Barthel, F. M. S., Royston, P., & Parmar, M. K. B. (2009). A menu-driven facility for sample-size calculation in novel multiarm, multistage randomized controlled trials with a time-to-event outcome. Stata Journal, 9(4), 505–523. https://doi.org/10.1177/1536867x0900900401

Readers over time

‘13‘14‘15‘16‘17‘19‘20‘21‘22‘23‘2400.751.52.253

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 6

55%

Researcher 4

36%

Professor / Associate Prof. 1

9%

Readers' Discipline

Tooltip

Medicine and Dentistry 2

29%

Economics, Econometrics and Finance 2

29%

Mathematics 2

29%

Decision Sciences 1

14%

Save time finding and organizing research with Mendeley

Sign up for free
0